- |||||||||| Journal, PD(L)-1 Biomarker, IO biomarker: 18F-BMS-986229 PET to Assess Programmed-Death Ligand 1 Status in Gastroesophageal Cancer. (Pubmed Central) - May 1, 2024
P
Patients treated with frontline programmed death 1 inhibitors who had 18F-BMS-986229 accumulation in any lesions on PET imaging had longer progression-free survival than patients without tracer accumulation in any lesions (median progression-free survival, 28.4 vs. 9.9?mo), though the small sample size prevents any definitive conclusions. PD-L1 PET imaging was safe, feasible, and concordant with pathologic evaluation and offers a potential noninvasive tool to assess PD-L1 expression.
- |||||||||| Opdivo (nivolumab) / BMS
Trial completion, Trial completion date, Trial primary completion date: A Study of PET Scans With the Radioactive Tracer 18F-BMS-986229 in Patients With Esophageal, Stomach, or Gastroesophageal Junction Cancer (clinicaltrials.gov) - Mar 12, 2024
P=N/A, N=10, Completed,
PD-L1 PET imaging was safe, feasible, and concordant with pathologic evaluation and offers a potential noninvasive tool to assess PD-L1 expression. Active, not recruiting --> Completed | Trial completion date: Nov 2024 --> Mar 2024 | Trial primary completion date: Nov 2024 --> Mar 2024
- |||||||||| Opdivo (nivolumab) / BMS
Enrollment closed, Enrollment change, Trial completion date, Trial primary completion date: A Study of PET Scans With the Radioactive Tracer 18F-BMS-986229 in Patients With Esophageal, Stomach, or Gastroesophageal Junction Cancer (clinicaltrials.gov) - Jun 7, 2022
P=N/A, N=10, Active, not recruiting,
Clinical trial information: NCT04161781. Recruiting --> Active, not recruiting | N=35 --> 10 | Trial completion date: Nov 2023 --> Nov 2024 | Trial primary completion date: Nov 2023 --> Nov 2024
- |||||||||| Opdivo (nivolumab) / Ono Pharma, BMS, Yervoy (ipilimumab) / Ono Pharma, BMS
Assessing PD-L1 without a biopsy and through PD-L1 PET imaging with 18F-BMS-986229. (Available On Demand; 233) - Apr 28, 2022 - Abstract #ASCO2022ASCO_1638;
P2
The signal of PD-L1 positivity by PET imaging with 18F-BMS-986229 at baseline appears associated with early efficacy from nivo + ipi in this small cohort and may offer additional information than PD-L1 IHC. The ability to assess PD-L1 on a whole patient level at multiple timepoints on treatment may have future implications in how best to sequence and combine immunotherapies but further study in larger patient cohorts is needed.
|
